Advertisement

 

 

Novel Oral Glucose Lowering Drugs Cut Risks in T2DM

Novel Oral Glucose Lowering Drugs Cut Risks in T2DM
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

WEDNESDAY, Feb. 8, 2017 (HealthDay News) — For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online Jan. 24 in Diabetes, Obesity and Metabolism.

Thomas Nyström, M.D., from Karolinska Institutet in Stockholm, and colleagues compared use of novel oral GLDs (either dipeptidyl-peptidase-4 inhibitors [DPP-4i] or sodium glucose cotransporter-2 inhibitors) with insulin treatment in a propensity score matched analysis involving 21,758 patients matched in a 1:1 ratio.

The researchers observed reductions in the risk of all-cause mortality, CVD, and hypoglycemia in the novel GLD group versus the insulin group (hazard ratios [HRs], 0.56 [95 percent confidence interval (CI), 0.49 to 0.64], 0.85 [95 percent CI, 0.73 to 0.99], and 0.26 [95 percent CI, 0.12 to 0.57], respectively). Dapagliflozin correlated with lower risks of all-cause mortality and CVD (HRs, 0.44 [95 percent CI, 0.28 to 0.70] and 0.51 [95 percent CI, 0.30 to 0.86], respectively), while DPP-4i correlated with reduced risk of all-cause mortality (HR, 0.59 [95 percent CI, 0.51 to 0.67]) but not CVD (HR, 0.87 [95 percent CI, 0.75 to 1.01]).

“Dapagliflozin was associated with lower risk of both all-cause mortality and CVD, whereas DPP-4i was only associated with lower risk of all-cause mortality,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

thirteen + nine =

[ HIDE/SHOW ]